ZYWIE LLC
Branding, marketing, and web development services
- Sector
- Biotech
- Headquarters
- JOHNS CREEK, GA
- Founded
- 2014
- Latest Form D
- $1.2M, Nov 2015
- Total capital
- $1.7M
- Federal grants
- $497K
- 1 award · 2025
- Rank in peer group#271 of 502
- Private capital raised
- $1.2M
- 1 Form D · last Nov 2015
- 132 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 8 pending · first 2026
- Rank in peer group#57 of 502
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Developing Novel Ambroxol Analogs as Disease-Modifying Therapies for Alzheimer's Disease and Related Dementias$497K
- Private capital raisedForm D · SEC · 1st filing$1.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#57 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- ALEX ARMSTRONGExecutive Officer, DirectorNamed in SEC Form D filings
- LATHA GANESHANExecutive Officer, DirectorNamed in SEC Form D filings
- MARTY SMITHDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 9- GrantedModified Forms Of Ambroxol For Therapeutic UseUSPTOUS 12,668,567
- PendingModified Forms Of Ambroxol For Therapeutic UseUSPTOApplication 18705344
- PendingModified Forms Of Ambroxol For Therapeutic UseUSPTOApplication 63499613
Show all 9 patent records
- Modified Forms Of Ambroxol For Therapeutic UseJun 30, 2026 · US 12,668,567Granted
- Modified Forms Of Ambroxol For Therapeutic UseJul 24, 2025 · Application 18705344Pending
- Modified Forms Of Ambroxol For Therapeutic UseApplication 63499613Pending
- Modified Forms Of Ambroxol For Therapeutic UseApplication PCTUS2022078779Pending
- Modified Forms Of Ambroxol For Therapeutic UseApplication 63272743Pending
- Use Of Ambroxol To Improve And/or Extend Healthspan, Lifespan And/or Mental AcuityApplication 62533071Pending
- Dual Chamber Syringe For Mixing And Dispensing Oral Liquid Pharmaceutical Dosage Forms Directly In The Mouth Of A PatientApplication PCTUS2016023877Pending
- High Drug Loading Liquid Oral Pharmaceutical CompositionsApplication PCTUS2016023783Pending
- Modified Forms Of Ambroxol For Therapeutic UseApplication PCTUS2024027209Pending
Related companies, and why
- Hillhurst Biopharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Agilvax, Inc.Similar federal contract value in Biotech · null in contracts
- RESOLUTE SCIENCE, INC.Similar federal contract value in Biotech · null in contracts
- ORPRO THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- BIOLYTX PHARMACEUTICALS CORPSimilar federal contract value in Biotech · null in contracts
- ALLOSTEROS THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .